{
  "scenario_id": "pharmaceutical_gene_therapy_regulatory_approval_2025",
  "context": "Biopharmaceutical company seeking FDA approval for novel gene therapy treatment for rare genetic disorder, requiring $180M investment over 36 months",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": ["CEO", "Board of Directors", "Chief Medical Officer"],
    "influencers": ["Regulatory Affairs Director", "Clinical Development Lead", "Commercial Strategy VP", "Chief Financial Officer"]
  },
  "request": {
    "amount": "$180,000,000",
    "purpose": "Complete Phase 3 clinical trials and submit BLA for gene therapy targeting cystic fibrosis variant",
    "urgency": "high",
    "justification": "Address $5B annual market for rare disease treatments with first-in-class therapy offering 70% improvement in lung function"
  },
  "decision_process": [
    {
      "stage": "scientific_review",
      "duration": "6 weeks",
      "activities": ["Preclinical data analysis", "Phase 2 results review", "Competitive landscape assessment"],
      "outcome": "Strong scientific foundation confirmed with clear clinical benefit"
    },
    {
      "stage": "regulatory_strategy",
      "duration": "8 weeks",
      "activities": ["FDA meeting preparation", "Regulatory pathway mapping", "CMC development planning"],
      "outcome": "Accelerated approval pathway identified with breakthrough therapy designation"
    },
    {
      "stage": "clinical_development_plan",
      "duration": "10 weeks",
      "activities": ["Phase 3 protocol design", "Site selection and recruitment planning", "Data management setup"],
      "outcome": "36-month development timeline with 800 patient enrollment target"
    },
    {
      "stage": "financial_modeling",
      "duration": "6 weeks",
      "activities": ["Cost projections", "Revenue forecasting", "Risk-adjusted NPV analysis"],
      "outcome": "Projected $2.1B NPV with 65% probability of success"
    },
    {
      "stage": "commercial_assessment",
      "duration": "4 weeks",
      "activities": ["Market access strategy", "Pricing and reimbursement analysis", "Launch planning"],
      "outcome": "$800M peak sales potential with 40% market share in addressable population"
    },
    {
      "stage": "executive_approval",
      "duration": "2 weeks",
      "activities": ["Board presentation", "Due diligence review", "Final investment committee approval"],
      "outcome": "Approved with $150M Phase 3 budget and $30M contingency"
    }
  ],
  "business_impact": {
    "expected_outcome": "First approved gene therapy for rare lung disease with $800M annual revenue potential",
    "projected_value": "$2,100,000,000",
    "risk_factors": ["Clinical trial failures", "Regulatory delays", "Manufacturing scalability issues", "Reimbursement challenges", "Competitor advancements"],
    "strategic_benefits": ["Platform technology validation for future gene therapies", "Rare disease market leadership", "Scientific reputation enhancement", "Partnership opportunities with patient advocacy groups"]
  },
  "decision_criteria": ["Scientific validity and clinical benefit", "Regulatory approval probability", "Financial viability and ROI", "Strategic alignment with pipeline", "Operational feasibility"],
  "outcome": "Approved",
  "lessons_learned": "Early regulatory engagement and breakthrough designation critical for accelerated timelines"
}